Clinical trials
for patients
Learn about available clinical trials
-
June 15, 2026PamplonaIn recruitment
C1071015 A TRIAL FOR PARTICIPANTS WITH MULTIPLE MYELOMA WHO HAVE PARTICIPATED IN PFIZER-SPONSORED CLINICAL TRIALS OF ELRANATAMAB
The objective of this study is to provide continued access to elranatamab (as monotherapy) and to monitor the safety of this drug in participants with multiple myeloma who continue to show clinical benefits in the Pfizer-sponsored main study, which is scheduled to conclude. -
June 15, 2026Pamplona/MadridIn recruitmentEarly phase
CTL-002-003 A randomized, double-blind, phase 2b comparative clinical trial investigating the efficacy and safety of visugromab compared with placebo
The objective of this study is to determine the safety and efficacy of a new drug called “visugromab” when administered in combination with immunochemotherapy -
June 10, 2026PamplonaIn recruitment
22931 Clinical trial conducted in humans to evaluate the safety of BAY 3713372 and how it works in participants with solid tumors with MTAP gene deletion
The aim of this trial is: -To see whether the new treatment BAY 3713372 has any effect, good or bad. -To find the best dose of BAY 3713372 to give to participants. -To understand what happens to BAY 3713372 once it is in the body. -To understand how the drug affects your body. -To understand how the treatment affects your disease. -To learn how different types and amounts of food affect the way the body absorbs the trial drug. -
June 10, 2026Pamplona/MadridIn recruitmentEarly phase
CTL-002-004 Randomized, blinded, placebo-controlled phase 2 clinical trial investigating the efficacy and safety of visugromab and nivolumab, with or without docetaxel, compared with docetaxel alone.
The aim of this clinical trial is to determine the efficacy of a new drug called “visugromab” (also known as “CT-L002”) and its safety when administered in combination with nivolumab and docetaxel. CT-L002 and nivolumab help the immune system fight cancer. Docetaxel interferes with the growth of cancer cells, leading to their destruction. CT-L002 has not yet been approved for any patients outside research studies. -
June 10, 2026Pamplona/MadridIn recruitmentEarly phase
M25-279 Phase II clinical study to evaluate the safety and efficacy of Telisotuzumab Adizutecan in the treatment of subjects with locally advanced or metastatic solid tumors with MET amplification.
The aim of this study is to evaluate the efficacy, safety and tolerability of Temab-A as monotherapy in patients with locally advanced or metastatic solid tumors with MET gene amplification. -
June 8, 2026Pamplona/MadridIn recruitmentEarly phase
CTL-002-005 A clinical trial investigating the efficacy and safety of visugromab in combination with nivolumab and lenvatinib compared with a double-blind placebo and lenvatinib in participants with unresectable or metastatic hepatocellular carcinoma and ....
The purpose of this trial is to determine how well a new drug currently in development called visugromab (also known as CTL-002) works and whether it is safe when used in combination with nivolumab and lenvatinib. -
June 3, 2026PamplonaIn recruitmentEarly phase
TV56286-NDG-20041 Ensayo clínico para describir la seguridad y la eficacia de TEV-56286 (Emrusolmin) en participantes con atrofia multisistémica
The objective of this study is to evaluate the long-term tolerability and safety of the investigational drug TEV-56286 in people with AMS. -
June 2, 2026Pamplona/MadridIn recruitment
STK-012-101 Phase I/II study of STK-012 as monotherapy and in combination therapy in solid tumors.
The primary objective of this study is to determine whether STK-012 administered together with standard-of-care treatment is more effective in treating cancer than standard-of-care treatment alone in patients with lung cancer. STK-012 is a new investigational drug being studied by the sponsor. -
June 2, 2026PamplonaIn recruitment
LB208-1-002 Multicenter, open-label, phase I/II study of LB-208, a selective antagonist of the 5-hydroxytryptamine serotonin receptor 1B (HTR1B), in adults with relapsed or refractory (r/r) acute myeloid leukemia (AML) and high-risk (HR) relapsed or refractory (r/r) myelodysplastic syndrome (MDS).
The objective of this trial, which involves research, is to examine the safety and efficacy of an investigational drug called LB-208. Investigational means that the investigational drug to be tested in this clinical trial has not been authorized by national drug regulatory agencies, such as the Spanish Agency of Medicines and Medical Devices. -
June 2, 2026MadridIn recruitmentEarly phase
2001-0001 Clinical trial to investigate how people with advanced cancer (solid tumors) tolerate different doses of BI 3820768.
Phase I study to determine the safety and tolerability of BI 3820768 in patients with advanced, relapsed, or treatment-refractory germ cell tumors, endometrial cancer, or ovarian cancer.